Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
Sales | 5,654,800 | 5,748,700 | 5,485,500 | 5,934,200 | 5,562,000 |
Cost of Goods | 987,600 | 1,023,900 | 1,122,500 | 1,431,300 | 1,051,900 |
Gross Profit | 4,667,200 | 4,724,800 | 4,363,000 | 4,502,900 | 4,510,100 |
Operating Expenses | 2,915,300 | 2,943,500 | 2,704,000 | 3,953,000 | 2,824,800 |
Operating Income | 1,752,500 | 1,782,200 | 1,659,500 | 550,200 | 1,686,200 |
Interest Expense | 0 | 0 | 47,600 | 0 | 0 |
Other Income | -81,200 | -45,700 | 95,900 | 587,000 | -616,700 |
Pre-tax Income | 1,671,300 | 1,736,500 | 1,707,800 | 1,137,200 | 1,069,500 |
Income Tax | 368,400 | 387,600 | 459,700 | 221,800 | 127,700 |
Net Income Continuous | 1,302,900 | 1,348,900 | 1,248,100 | 915,400 | 941,800 |
Net Income | $1,302,900 | $1,348,900 | $1,248,100 | $915,400 | $941,800 |
EPS Basic Total Ops | 1.18 | 1.22 | 1.13 | 0.82 | 0.86 |
EPS Basic Continuous Ops | 1.18 | 1.23 | 1.14 | 0.82 | 0.86 |
EPS Diluted Total Ops | 1.18 | 1.22 | 1.13 | 0.82 | 0.86 |
EPS Diluted Continuous Ops | 1.18 | 1.22 | 1.13 | 0.83 | 0.86 |
EBITDA(a) | $2,097,200 | $2,127,800 | $1,958,900 | $926,000 | $1,995,900 |